Caplacizumab (Cablivi)

Decision Date:
June 2020


RED1,2,3,8: NICE TA667 - Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura. (Decision date - January 2021) 

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire CCG

Derby and Derbyshire CCG